Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

TA212 Colorectal cancer (metastatic) - bevacizumab: review decision - July 2013 information

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix A decision paper presented to the Institute's Guidance Executive (PDF 102 KB)

TA212 Colorectal cancer (metastatic) - bevacizumab: review proposal - May 2013 information

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix A - provisional matrix of stakeholders (PDF 111 KB)

TA212 Colorectal cancer (metastatic) - bevacizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 275 KB)

Colorectal cancer (metastatic) - bevacizumab: Equality Impact Assessment form (PDF 68 KB)

Colorectal cancer (metastatic) - bevacizumab: final appraisal determination information

Colorectal cancer (metastatic) - bevacizumab: final appraisal determination (PDF 237 KB)

Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the ACD and comments from website consultation

Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the first ACD and comments from website consultation (Issued November 2009) (PDF 170 KB)

Colorectal cancer (metastatic) - bevacizumab: response to consultee, commentator and public comments on the second ACD and comments from website consultation (Issued August 2010) (PDF 242 KB)

Colorectal cancer (metastatic) - bevacizumab: ERG Additional Analyses - cost of oxaliplatin (PDF 7.3 KB)

Colorectal cancer (metastatic) - bevacizumab: consultee and commentator comments on the ACD

Colorectal cancer (metastatic) - bevacizumab: Roche (PDF 125 KB)

Colorectal cancer (metastatic) - bevacizumab: Bowel Cancer UK (PDF 51 KB)

Colorectal cancer (metastatic) - bevacizumab: Royal College of Nursing (PDF 55 KB)

Colorectal cancer (metastatic) - bevacizumab: National Collaborating Centre for Cancer (PDF 124 KB)

Colorectal cancer (metastatic) - bevacizumab: appraisal consultation 

Colorectal cancer (metastatic) - bevacizumab: appraisal consultation document information

Colorectal cancer (metastatic) - bevacizumab: evaluation report

Colorectal cancer (metastatic) - bevacizumab: evidence review group response (PDF 19 KB)

Colorectal cancer (metastatic) - bevacizumab: letter from the Department of Health information

Colorectal cancer (metastatic) - bevacizumab: letter from the Department of Health (PDF 24 KB)

Colorectal cancer (metastatic) - bevacizumab: critique by the evidence review group of the additional analyses and amended model provided by the manufacturers (PDF 34 KB)

Colorectal cancer (metastatic) - bevacizumab: patient access scheme template submitted by Roche information

Colorectal cancer (metastatic) - bevacizumab: PAS template (PDF 112 KB)

Colorectal cancer (metastatic) - bevacizumab: draft fax back form (PDF 29 KB)

Colorectal cancer (metastatic) - bevacizumab: PSA analysis submitted by Roche (PDF 27 KB)

Colorectal cancer (metastatic) - bevacizumab: response to ACD1 from consultees and commentators

Colorectal cancer (metastatic) - bevacizumab: Roche

Colorectal cancer (metastatic) - bevacizumab: ACD response (PDF 115 KB)

Colorectal cancer (metastatic) - bevacizumab: operating costs (PDF 48 KB)

Colorectal cancer (metastatic) - bevacizumab: time and motion results (PDF 105 KB)

Colorectal cancer (metastatic) - bevacizumab: administration costs (PDF 90 KB)

Colorectal cancer (metastatic) - bevacizumab: Bowel Cancer UK (PDF 78 KB)

Colorectal cancer (metastatic) - bevacizumab: appraisal consultation document

Colorectal cancer (metastatic) - bevacizumab: appraisal consultation document information

Colorectal cancer (metastatic) - bevacizumab: evaluation report

Pre-meeting briefing (PDF 197 KB)

Evidence review group report

ERG report (PDF 632 KB)

ERG additional information (PDF 23 KB)

ERG additional analyses (PDF 16 KB)

Clarification

NICE Clarification letter (PDF 55 KB)

Response to clarification letter 1 (PDF 21.68 MB)

Response to clarification letter 2 (PDF 63 KB)

Response to clarification letter 3 (PDF 46 KB)

Response to clarification letter 4 (PDF 168 KB)

Non-manufacturer submissions

Royal College of Nursing (PDF 13 KB)

Royal College of Physicians (PDF 43 KB)

Bowel Cancer UK Submission (PDF 58 KB)

Beating bowel cancer submission (PDF 77 KB)

Manufacturer submission

Manufacturer submission (PDF 9.95 MB)

Manufacturer submission: appendix 1 (PDF 186 KB)

Manufacturer submission: appendix 2 (PDF 79 KB)

Manufacturer submission: appendix 3 (PDF 208 KB)

Manufacturer submission: PAS template (PDF 118 KB)

Expert statement: Barbara Moss (PDF 53 KB)

Colorectal cancer (metastatic) - bevacizumab: final scope (PDF 27 KB)

Colorectal cancer (metastatic) - bevacizumab: final matrix of consultees and commentators (PDF 35 KB)

Colorectal cancer (metastatic) - bevacizumab: response to comments on the draft scope (PDF 58 KB)

Colorectal cancer (metastatic) - bevacizumab: response to comments on the provisional matrix (PDF 17 KB)

Colorectal cancer (metastatic) - bevacizumab: draft scope (PDF 34 KB)

Colorectal cancer (metastatic) - bevacizumab: provisional matrix of consultees and commentators - pre-referral (PDF 36 KB)